Literature DB >> 30754041

The Current Indications for Non-Surgical Treatment of Hypopharyngeal Cancer.

Remco de Bree1.   

Abstract

The management of hypopharyngeal cancer is challenging because of poor patient survival and the potential effects of treatment on breathing, voice and swallowing. In general, early stage hypopharyngeal cancer can be primarily treated by radiotherapy or conservative transoral or open surgery, whereas advanced stage hypopharyngeal cancer can be treated by non-surgical protocols if the patient has no loss of functions (dysfunctional larynx) and/or cartilage invasion (T4a). Factors to determine individualized patient treatment include resectability, tumour volume, distant metastases, comorbidity, age, patient's preference, functional imaging parameters, response on induction chemotherapy and employing functional imaging parameters performed in the pre-treatment phase and repeated in the early treatment phase when employing a non-surgical treatment strategy.
© 2019 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2019        PMID: 30754041     DOI: 10.1159/000492314

Source DB:  PubMed          Journal:  Adv Otorhinolaryngol        ISSN: 0065-3071


  3 in total

1.  Magnetic resonance imaging-derived radiomic signature predicts locoregional failure after organ preservation therapy in patients with hypopharyngeal squamous cell carcinoma.

Authors:  Che-Yu Hsu; Shih-Min Lin; Ngan Ming Tsang; Yu-Hsiang Juan; Chun-Wei Wang; Wei-Chung Wang; Sung-Hsin Kuo
Journal:  Clin Transl Radiat Oncol       Date:  2020-08-31

2.  A Nomogram for Pretreatment Prediction of Response to Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma.

Authors:  Baoliang Guo; Fusheng Ouyang; Lizhu Ouyang; Xiyi Huang; Haixiong Chen; Tiandi Guo; Shao-Min Yang; Wei Meng; Ziwei Liu; Cuiru Zhou; Qiu-Gen Hu
Journal:  Front Oncol       Date:  2020-12-11       Impact factor: 6.244

3.  Laryngeal Squamous Cell Carcinoma: Potential Molecular Mechanism and Prognostic Signature Based on Immune-Related Genes.

Authors:  Bin-Yu Mo; Guo-Sheng Li; Su-Ning Huang; Zhu-Xin Wei; Ya-Si Su; Wen-Bin Dai; Lin Ruan
Journal:  Med Sci Monit       Date:  2020-12-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.